Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emergent BioSolutionsEBS -1.43%65 Debt-to-Equity is 1.70 as of Jun. 2026, which is 130% above its 10-year median of 0.74. GuruFocus rates EBS with a GF Score™ of 65/100 and a GF Value™ of $5.47 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 809 Drug Manufacturers companies, Emergent BioSolutions ranks worse than 93.57% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Emergent BioSolutions's Debt-to-Equity or its related term are showing as below:
EBS'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.74 Max: 2.23
Current: 1.7
During the past 13 years, the highest Debt-to-Equity Ratio of Emergent BioSolutions was 2.23. The lowest was 0.01. And the median was 0.74.
EBS's Debt-to-Equity is ranked worse than 93.57% of 809
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs EBS: 1.70
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Emergent BioSolutions Debt-to-Equity Related Terms
Emergent BioSolutions Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Emergent BioSolutions's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBS vs EOLS, ELTP, AKBA: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emergent BioSolutions Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions (EBS) has a Debt-to-Equity of 1.70 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Emergent BioSolutions and its competitors. This is 130% above median its historical median of 0.74. Over the past decade, Emergent BioSolutions' Debt-to-Equity has ranged from 0.01 to 2.23. According to the industry distribution chart, Emergent BioSolutions ranks #757 out of 809 companies in the Drug Manufacturers industry, placing it in the top 93.6%.
Is Emergent BioSolutions' Debt-to-Equity too high?
Emergent BioSolutions' current Debt-to-Equity of 1.70 is 130% above median its 10-year median of 0.74. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 2.23. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Emergent BioSolutions' value of 1.70 is 507.1% above this industry median. Based on the distribution chart, Emergent BioSolutions ranks #757 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Emergent BioSolutions has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Debt-to-Equity compare to EOLS and ELTP?
According to the Drug Manufacturers industry distribution chart, Emergent BioSolutions ranks #757 out of 809 companies for Debt-to-Equity. This places Emergent BioSolutions in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Emergent BioSolutions' value of 1.70 is 507.1% above this benchmark. Historically, Emergent BioSolutions' own Debt-to-Equity has ranged from 0.01 to 2.23 over the past decade. While the company's 10-year median is 0.74 vs. the industry median of 0.28, Emergent BioSolutions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emergent BioSolutions's current Debt-to-Equity of 1.70 is 507.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Emergent BioSolutions and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emergent BioSolutions's current Debt-to-Equity is 1.70, which is 130% above median its own 10-year median of 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (EBS) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.47, compared to a current price of $4.82 — trading 11.9% below its estimated fair value. The current Debt-to-Equity is 1.70, which is 130% above median its 10-year median of 0.74 and 507.1% above the Drug Manufacturers industry median of 0.28. Emergent BioSolutions' overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Emergent BioSolutions (EBS), the current Debt-to-Equity is 1.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emergent BioSolutions (EBS) Overvalued in 2026?
Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be undervalued.
The current stock price of $4.82 is trading 11.9% below its estimated GF Value™ of $5.47.
GuruFocus considers Emergent BioSolutions to be Modestly Undervalued.
Key valuation signals for EBS:
Debt-to-Equity: 1.70 (130% above median its 10-year median of 0.74)
GF Value™: $5.47 vs. price of $4.82 (11.9% below fair value)
Industry Position: 507.1% above the Drug Manufacturers median (#757 of 809)
No single metric tells the full story. See the EBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
65GF Score
Get the complete analysis for EBS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EBS has been successfully added to your 
